SCHEMBL595279

SCHEMBL595279

COc1ccc([O])c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.62
CA1 P00915 2/20 0.62
CA2 P00918 2/20 0.62
CA7 P43166 2/20 0.62
CA9 Q16790 2/20 0.62
CA14 Q9ULX7 2/20 0.62
ALDH1A1 P00352 7/20 0.55
CYP1A1 P04798 6/20 0.54
CYP1A2 P05177 6/20 0.54
CYP1B1 Q16678 6/20 0.54
CYP3A4 P08684 2/20 0.54
NPC1 O15118 1/20 0.48
CYP2E1 P05181 1/20 0.48
CYP2C8 P10632 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2A6 P11509 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP4B1 P13584 1/20 0.48
CYP2B6 P20813 1/20 0.48
CYP3A5 P20815 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1045690 0.81 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL11786846 0.80 ACHE (0.50) CA12CA1CA2CA7CA9
SCHEMBL3033181 0.80 RUNX1 (0.42) CA12CA1CA2CA7CA9
SCHEMBL9487248 0.78 CA12 (0.81) CA12CA1CA2CA7CA9
1,2,4-Trimethoxybenzene SCHEMBL29350371 0.77 CA12 (1.00) CA12CA1CA2CA7CA9
1,2,4-Trimethoxybenzene SCHEMBL481491 0.77 CA12 (1.00) CA12CA1CA2CA7CA9
1,2,4-Trimethoxybenzene SCHEMBL27777905 0.77 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL1402343 0.77 CA12 (0.52) CA12CA1CA2CA7CA9
SCHEMBL1802754 0.76 ACHE (0.62) CA1CA2CA9ALDH1A1CYP3A4
SCHEMBL4396937 0.76 CYP1A2 (0.48) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104447646-B A kind of method complete synthesis for natural product Moracin M 中科院广州化学有限公司 2016-08-31 CN claimed
EP-0772616-B1 HYDROPHILIC METAL COMPLEXES ROCHE DIAGNOSTICS GMBH (DE) 1999-12-15 EP claimed
US-5541032-A CHARGE STABILIZERS WHICH ARE INSENSITIVE TO MOISTURE, HEAT RESISTANT AND PRODUCE CRISP, UNIFORM VISIBLE IMAGES OF HIGH COLOR INTENSITY BASF AKTIENGESELLSCHAFT (DE) 1996-07-30 US claimed
US-12043573-B2 Adhesion promoters and gel-modifiers for olefin metathesis compositions MATERIA, INC. (US) 2024-07-23 US disclosed
EP-3386936-B1 OLEFIN METATHESIS CATALYSTS UMICORE AG & CO KG (DE) 2024-07-10 EP disclosed
CN-113423549-B Coating composition 马特里亚公司 2024-06-25 CN disclosed
EP-3016991-B1 LIQUID MOLDING COMPOSITIONS MATERIA INC (US) 2024-06-12 EP disclosed
WO-2024097151-A1 ANTIBIOTIC-RESISTANT ARTIFICIAL NUCLEOSIDE, COMPOSITION AND METHOD CLEVELAND STATE UNIVERSITY (US) 2024-05-10 WO disclosed
US-11958042-B2 Reactions of olefin derivatives in the presence of metathesis catalysts UMICORE AG & CO. KG (DE) 2024-04-16 US disclosed
CN-110770230-B Production of trimethylbenzene derivatives 罗地亚经营管理公司 2024-03-26 CN disclosed
US-20240092764-A1 KINASE INHIBITORS INSILICO MEDICINE IP LIMITED (HK) 2024-03-21 US disclosed
EP-0422474-A2 Fluorescent pigments BASF Aktiengesellschaft (DE) 1991-04-17 EP disclosed
EP-0387613-A1 Thienodiazepines BOEHRINGER INGELHEIM KG (DE) 1990-09-19 EP disclosed
US-4898654-A IRRADIATING INCLUSION COMPLEX OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1990-02-06 US disclosed
EP-0351615-A1 Process for the preparation of 4-alkoxy-2-hydroxybenzophenone-5-sulfonic acids BASF Aktiengesellschaft (DE) 1990-01-24 EP disclosed
US-4820703-A TREATMENT OF INFLAMMATORY, RESPIRATORY AND CARDIOVASCULAR DISEASES YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD. (JP) 1989-04-11 US disclosed
EP-0284099-A2 Silver halide color photographic materials FUJI PHOTO FILM CO., LTD. (JP) 1988-09-28 EP disclosed
EP-0268242-A1 PAF-antagonistic thienotriazolodiazepine compounds and pharmaceutical uses thereof Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1988-05-25 EP disclosed
EP-0247381-A2 5-flurorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-12-02 EP disclosed
US-4309441-A HYPOTENSIVE AGENTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1982-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092764-A1 KINASE INHIBITORS MAP4K4, MAP2K4, MAP4K2 CA12 4531/4885CA1 3936/4885CA2 2121/4885
US-11958042-B2 Reactions of olefin derivatives in the presence of metathesis catalysts SYMPK, MDK, HCK CA12 3786/4885CA1 3425/4885CA2 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.